Phase II study evaluating efficacy and tolerability of Sorafenib in the treatment of iatrogenic lymphedema occurring in breast cancer patients following surgical dissection of, and/or radiotherapy on axillary lymphnodes

Trial Profile

Phase II study evaluating efficacy and tolerability of Sorafenib in the treatment of iatrogenic lymphedema occurring in breast cancer patients following surgical dissection of, and/or radiotherapy on axillary lymphnodes

Recruiting
Phase of Trial: Phase II

Latest Information Update: 09 Oct 2013

At a glance

  • Drugs Sorafenib (Primary)
  • Indications Breast cancer; Lymphoedema; Male breast cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 09 Oct 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top